Familial Mediterranean Fever Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, And Companies

DelveInsight's “Familial Mediterranean Fever Pipeline Insight 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Familial Mediterranean Fever pipeline landscape. It covers the Familial Mediterranean Fever pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Familial Mediterranean Fever therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Familial Mediterranean Fever Pipeline. Dive into DelveInsight's comprehensive report today! @ Familial Mediterranean Fever Pipeline Outlook

Key Takeaways from the Familial Mediterranean Fever Pipeline Report

• On August 27, 2025, the University of São Paulo General Hospital initiated a Phase 4 randomized prospective study involving adult patients with autoimmune rheumatic diseases (ARDs). Participants will receive two intramuscular doses of RZV administered six weeks apart. A control group (CG) consisting of non-immunosuppressed individuals aged ≥50 years will also be included, in a ratio of three patients to one control. Patients with ARDs will be randomly assigned to two groups, P1 and P2. Both the CG and P1 groups will receive the vaccine immediately after randomization, on Day 0 (D0) and Day 42 (D42).
• DelveInsight's Familial Mediterranean Fever Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Familial Mediterranean Fever treatment.
• The leading Familial Mediterranean Fever Companies such as Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals , and others.
• Promising Familial Mediterranean Fever Pipeline Therapies such as Canakinumab, RPH-104, ACZ885, Dusquetide, AIN457, Apremilast, Infliximab, Apremilast , and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Familial Mediterranean Fever Treatment Drugs

Familial Mediterranean Fever Emerging Drugs Profile

• Tocilizumab: Roche

Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.

The Familial Mediterranean Fever Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Familial Mediterranean Fever with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Familial Mediterranean Fever Treatment.
• Familial Mediterranean Fever Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Familial Mediterranean Fever Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Familial Mediterranean Fever market

Explore groundbreaking therapies and clinical trials in the Familial Mediterranean Fever Pipeline. Access DelveInsight's detailed report now! @ New Familial Mediterranean Fever Drugs

Familial Mediterranean Fever Companies

Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals , and others.

Familial Mediterranean Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Parenteral
• Intramuscular
• Molecule Type

Familial Mediterranean Fever Products have been categorized under various Molecule types such as

• Small molecules
• Peptides
• Polymer
• Gene Therapy
• Monoclonal antibodies
• Product Type

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Familial Mediterranean Fever Market Drivers and Barriers

Scope of the Familial Mediterranean Fever Pipeline Report

• Coverage- Global
• Familial Mediterranean Fever Companies- Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals , and others.
• Familial Mediterranean Fever Pipeline Therapies- Canakinumab, RPH-104, ACZ885, Dusquetide, AIN457, Apremilast, Infliximab, Apremilast , and others.
• Familial Mediterranean Fever Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Familial Mediterranean Fever Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's in-depth pipeline report today! @ Familial Mediterranean Fever Companies, Key Products and Unmet Needs

Table of Contents